CA2322315A1 - Fast disintegrating tablets - Google Patents

Fast disintegrating tablets Download PDF

Info

Publication number
CA2322315A1
CA2322315A1 CA002322315A CA2322315A CA2322315A1 CA 2322315 A1 CA2322315 A1 CA 2322315A1 CA 002322315 A CA002322315 A CA 002322315A CA 2322315 A CA2322315 A CA 2322315A CA 2322315 A1 CA2322315 A1 CA 2322315A1
Authority
CA
Canada
Prior art keywords
fast disintegrating
disintegrating tablets
seconds
less
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002322315A
Other languages
French (fr)
Other versions
CA2322315C (en
Inventor
Luca Dobetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharmaceuticals SRL
Original Assignee
Eurand International S.P.A.
Luca Dobetti
Eurand S.P.A.
Aptalis Pharma S.R.L.
Adare Pharmaceuticals S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8231542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2322315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand International S.P.A., Luca Dobetti, Eurand S.P.A., Aptalis Pharma S.R.L., Adare Pharmaceuticals S.R.L. filed Critical Eurand International S.P.A.
Publication of CA2322315A1 publication Critical patent/CA2322315A1/en
Application granted granted Critical
Publication of CA2322315C publication Critical patent/CA2322315C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Abstract

This invention provides a formulation for preparing a fast disintegrating tablet comprising a drug in multiparticulate form, one or more water insoluble inorganic excipients, one or more disintegrants; and optionally one or more substantially water soluble excipients, the amounts of said ingredients being such as to provide a disintegration time for the tablet in the order of 75 seconds or less, typically 30 seconds or less.
CA002322315A 1998-03-06 1999-03-04 Fast disintegrating tablets Expired - Fee Related CA2322315C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98104035 1998-03-06
EP98104035.5 1998-03-06
PCT/EP1999/001395 WO1999044580A1 (en) 1998-03-06 1999-03-04 Fast disintegrating tablets

Publications (2)

Publication Number Publication Date
CA2322315A1 true CA2322315A1 (en) 1999-09-10
CA2322315C CA2322315C (en) 2008-09-16

Family

ID=8231542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322315A Expired - Fee Related CA2322315C (en) 1998-03-06 1999-03-04 Fast disintegrating tablets

Country Status (15)

Country Link
US (1) US6596311B1 (en)
EP (1) EP1058538B9 (en)
JP (1) JP2002505269A (en)
KR (1) KR20010041609A (en)
AR (1) AR018143A1 (en)
AT (1) ATE219658T1 (en)
AU (1) AU741992B2 (en)
BR (1) BR9908438A (en)
CA (1) CA2322315C (en)
DE (1) DE69901938T3 (en)
DK (1) DK1058538T3 (en)
ES (1) ES2178876T5 (en)
NZ (1) NZ507271A (en)
PT (1) PT1058538E (en)
WO (1) WO1999044580A1 (en)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
CA2348452A1 (en) * 1998-10-27 2000-05-04 Biovail Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US7799342B2 (en) 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US6814978B2 (en) * 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US20020122823A1 (en) * 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
GB0113843D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
FR2834893B1 (en) * 2002-01-23 2004-02-27 Servier Lab ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF PERINDOPRIL
FR2834896B1 (en) * 2002-01-23 2004-02-27 Servier Lab ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF IVABRADINE
FR2834890B1 (en) * 2002-01-23 2004-02-27 Servier Lab ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF AGOMELATIN
GB0204771D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US6753009B2 (en) * 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
FR2838647B1 (en) * 2002-04-23 2006-02-17 PROLONGED RELEASE PARTICLES, PROCESS FOR THEIR PREPARATION AND TABLETS CONTAINING SAME
FR2845914B1 (en) * 2002-10-18 2005-11-04 Schwarz Pharma Lab ANTIEMETIC COMPOUND WITH RAPID DISAGGREGATION
WO2004047810A1 (en) * 2002-11-25 2004-06-10 Purdue Research Foundation Mannose-based fast dissolving tablets
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
KR101099176B1 (en) 2003-01-21 2011-12-27 니뽄 신야쿠 가부시키가이샤 Tablet quickly melting in oral cavity
CA2524806C (en) * 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
BRPI0411039A (en) 2003-06-06 2006-07-11 Ethypharm Sa orodispersibly multilayer tablet
WO2005018678A1 (en) * 2003-08-26 2005-03-03 Ezaki Glico Co., Ltd. Additives for tablet
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
DK1663182T4 (en) 2003-09-12 2020-02-17 Amgen Inc Fast dissolving formulation of cinacalcet HCl
DE10351448A1 (en) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Flavor-containing drug formulations with improved pharmaceutical properties
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US20070196476A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area titanium dioxide
US20050244493A1 (en) * 2004-04-30 2005-11-03 Withiam Michael C Rapidly disintegrating tablets comprising calcium carbonate
US20050244492A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Rapidly disintegrating tablets comprising titanium dioxide
US20050244343A1 (en) * 2004-04-30 2005-11-03 Withiam Michael C Oral care products comprising silica
US20070196477A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area calcium phosphates
US20070196475A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising silica materials
US20070196474A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising calcium carbonate
US20050244347A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Oral care products comprising calcium phosphates
US20070212416A1 (en) * 2004-06-10 2007-09-13 Glatt Air Techniques, Inc. Controlled Release Matrix Pharmaceutical Dosage Formulation
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
ITMI20042356A1 (en) 2004-12-10 2005-03-10 Acraf ORODISPERSIBLE PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR PREPARING IT
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
JP5004236B2 (en) * 2005-02-09 2012-08-22 キッセイ薬品工業株式会社 Orally disintegrating tablets
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
KR100990590B1 (en) * 2005-09-01 2010-10-29 에자이 알앤드디 매니지먼트 가부시키가이샤 Method for preparation of pharmaceutical composition having improved disintegratability
DK1928409T3 (en) 2005-09-12 2012-11-05 Actelion Pharmaceuticals Ltd STABLE PHARMACEUTICAL COMPOSITION INCLUDING PYRIMIDINE SULFAMIDE
FR2891147B1 (en) * 2005-09-28 2007-12-07 Ethypharm Sa ORODISPERSIBLE TABLETS OF ACTIVE AMER PRINCIPLES
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070116759A1 (en) * 2005-11-22 2007-05-24 Gershon Kolatkar Pharmaceutical compositions of telmisartan
US20090030057A1 (en) * 2005-11-22 2009-01-29 Shlomit Wizel Pharmaceutical composition of telmisartan
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
BRPI0707325A2 (en) * 2006-01-27 2011-05-03 Eurand Inc multiparticulate release dosage formulation and method for preparing same
KR101413613B1 (en) * 2006-01-27 2014-07-10 앱탈리스 파마테크, 인코포레이티드 Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
WO2007091856A1 (en) * 2006-02-10 2007-08-16 Lg Household & Health Care Ltd. In-situ melting and gelling tablet composition for oral care
US20090312439A1 (en) * 2006-05-10 2009-12-17 Ralph Hofmann Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
US8377994B2 (en) 2006-05-10 2013-02-19 Evonik Degussa GmeH Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
WO2008015220A1 (en) 2006-08-04 2008-02-07 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
DE602007005653D1 (en) 2006-08-04 2010-05-12 Ethypharm Sa MULTILAYER MOUTH-CATCHING TABLET
EP2050448A4 (en) * 2006-08-08 2012-01-04 Kissei Pharmaceutical Oral disintegrating tablet having masked bitter taste and method for production thereof
WO2008018086A1 (en) * 2006-08-10 2008-02-14 Bajaj Healthcare Limited Mouth dissolving pharmaceutical or nutraceutical composition
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
EP2069062A2 (en) * 2006-10-06 2009-06-17 The President and Fellows of Harvard College Chemically-directed electrostatic self-assembly of materials
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
AU2007338751A1 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
ES2645255T3 (en) 2007-10-01 2017-12-04 Laboratorios Lesvi, S.L. Orodispersible tablets
GB0720220D0 (en) * 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
WO2009058798A2 (en) * 2007-10-31 2009-05-07 Mcneil-Ppc, Inc. Orally disintegrated dosage form
ES2455195T3 (en) * 2007-11-21 2014-04-14 Dainippon Sumitomo Pharma Co., Ltd. Tablet that disintegrates in the oral cavity
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
EP2433652B1 (en) 2009-05-20 2016-11-09 Sumitomo Dainippon Pharma Co., Ltd. Dry-coated orally-disintegrating tablet
JP5575119B2 (en) * 2009-05-20 2014-08-20 大日本住友製薬株式会社 Orally disintegrating tablets
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US9610224B2 (en) 2009-09-24 2017-04-04 Johnson & Johnson Consumer Inc. Manufacture of tablet in a die utilizing powder blend containing water-containing material
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
BR122022005637B1 (en) 2009-10-01 2023-03-07 Adare Pharmaceuticals, Inc NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION
CN108159019A (en) 2009-12-02 2018-06-15 阿黛尔药物有限公司 Fexofenadine microcapsules and the composition containing fexofenadine microcapsules
US20110150993A1 (en) * 2009-12-22 2011-06-23 Fmc Corporation Fine Particle Croscarmellose and Uses Thereof
TW201127375A (en) * 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
EP2377522B1 (en) * 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9433620B2 (en) 2011-05-13 2016-09-06 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
TWI488659B (en) * 2011-05-25 2015-06-21 Taiho Pharmaceutical Co Ltd Containing tegafur, gemcitabine, and otiracazide
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
JP6245677B2 (en) * 2012-01-20 2017-12-13 ニプロ株式会社 Orally disintegrating tablets
EP2810659B1 (en) 2012-02-03 2017-08-09 Asahi Kasei Kabushiki Kaisha Orally disintegrating tablet containing bitterness-masking granules
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
AU2012379005B2 (en) 2012-05-02 2017-12-21 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
WO2013180249A1 (en) 2012-05-31 2013-12-05 旭化成ケミカルズ株式会社 Cellulose powder
BR112015009004A8 (en) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd amorphous form of quinoline derivative and method of production thereof
ITMI20130210A1 (en) * 2013-02-14 2014-08-15 Menarini Lab PHARMACEUTICAL COMPOSITIONS CONTAINING DEXKETOPROPHENES AND TRAMADOL
GB201303781D0 (en) * 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
ES2687968T3 (en) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarkers to predict and evaluate the reactivity of subjects with endometrial cancer to compounds with lenvatinib
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
BR112016015944A8 (en) 2014-01-10 2020-06-09 Johnson & Johnson Consumer Inc process to produce tablet, which uses radiofrequency and coated particles dissipating energy
HRP20221047T1 (en) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
PT3263106T (en) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
RU2729936C2 (en) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Anticancer agent
EP3389600B1 (en) * 2015-12-18 2022-02-02 Colgate-Palmolive Company Fast dissolving peroxymonosulfate composition
WO2017112672A1 (en) 2015-12-23 2017-06-29 Colgate-Palmolive Company Storage-stable solid peroxymonosulfate composition
EP3484588B1 (en) 2016-08-11 2023-07-26 Colgate-Palmolive Company Peroxymonosulfate toothpowder composition for tenacious stains
TWI777515B (en) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 Methods of treating eosinophilic esophagitis
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US20210290550A1 (en) * 2018-07-27 2021-09-23 Sandoz Ag Process for Preparing Rapidly or Very Rapidly Dissolving Tablets Comprising Freely Soluble API
US20220233415A1 (en) 2021-01-25 2022-07-28 Colgate-Palmolive Company Solid Oral Care Compositions
US20220339082A1 (en) 2021-04-23 2022-10-27 Colgate-Palmolive Company Solid Oral Care Compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH20837A (en) * 1983-04-29 1987-05-08 Pennwalt Corp Rapid dissolving uniform drug compositon
US4866046A (en) 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
HU201869B (en) * 1988-12-30 1991-01-28 Egyt Gyogyszervegyeszeti Gyar Process for producing microcapsules of quick dissolving active component
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (en) * 1991-07-22 1994-09-09 Prographarm Laboratoires MULTIPARTICLE TABLET WITH RAPID DELIVERY.
JP3069458B2 (en) * 1992-01-29 2000-07-24 武田薬品工業株式会社 Orally disintegrating tablet and production method thereof
US5635210A (en) * 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
MX9706062A (en) * 1995-02-08 1997-10-31 Yamanouchi Europ Bv ORAL DOSAGE-FORMS CONTAINING A 'beta'-LACTAM ANTIBIOTIC.
DE19530575A1 (en) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Rapidly disintegrating drug form of tramadol or a tramadol salt
ES2217410T3 (en) * 1996-04-16 2004-11-01 Novartis Consumer Health S.A. ORAL DOSAGE FORM OF FAST DISINTEGRATION.
KR20050071718A (en) * 1996-07-12 2005-07-07 다이이찌 세이야꾸 가부시기가이샤 Quickly disintegratable compression-molded materials and process for producing the same
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions

Also Published As

Publication number Publication date
EP1058538B1 (en) 2002-06-26
ES2178876T3 (en) 2003-01-01
DE69901938T2 (en) 2002-10-10
DE69901938T3 (en) 2012-08-02
AR018143A1 (en) 2001-10-31
JP2002505269A (en) 2002-02-19
KR20010041609A (en) 2001-05-25
NZ507271A (en) 2003-03-28
EP1058538B2 (en) 2012-04-11
CA2322315C (en) 2008-09-16
PT1058538E (en) 2002-11-29
AU2727799A (en) 1999-09-20
ATE219658T1 (en) 2002-07-15
DE69901938D1 (en) 2002-08-01
DK1058538T3 (en) 2002-10-21
EP1058538B9 (en) 2013-01-02
WO1999044580A1 (en) 1999-09-10
US6596311B1 (en) 2003-07-22
AU741992B2 (en) 2001-12-13
EP1058538A1 (en) 2000-12-13
ES2178876T5 (en) 2012-10-01
BR9908438A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
CA2322315A1 (en) Fast disintegrating tablets
FI20011852A (en) A process for the preparation of a dispersible tablet containing fluoxetine or an acid addition salt thereof
WO2002074238A3 (en) Water soluble and palatable complexes
AU1729397A (en) Process to prepare soluble delivery systems using volatile salts
CA2301135A1 (en) Rapidly disintegrating methylcellulose tablets
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
MY125766A (en) Flash-melt oral dosage formulation
MY137768A (en) Rapidly disintegrating methylcellulose tablets
ZA200301813B (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
CA2371940A1 (en) Pregelatinized starch in a controlled release formulation
EP0890359A4 (en)
HUP0102206A2 (en) Delavirdine tablet formulation
MY127908A (en) Improved pharmaceutical formulations.
BG108516A (en) Pharmaceutical formulation
MY128896A (en) Pharmaceutical combinations
HUP0200363A2 (en) Lhrh antagonist decapeptides, pharmaceutical compositions comprising thereof and processes for their preparation
MXPA04003346A (en) Flashmelt oral dosage formulation.
BR0013106A (en) Floating pharmaceutical composition, tablet, and tablet preparation process.
WO2001034118A3 (en) Solid dispersion pharmaceutical formulations
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
GEP20043377B (en) Pharmaceutical Complex
BG108807A (en) Amlodipine bezylate tablets with improved stability
WO2001030324A3 (en) Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia
CA2285852A1 (en) Pharmaceutical tablet comprising lisinopril disodium and microcrystalline cellulose
HU0101360D0 (en) Process for the preparation of easily compressible tablets from pharmaceutically active agents with poor tablet formulation characteristics

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170306